OKYO Pharma Limited
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $79.2M
- Price
- $1.51
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.66%
- Volume
- 47.0K
About
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Quick stats
Shares outstanding52.5M
Computed float39.2M
Float / shares74.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001849296
Websitehttps://www.okyopharma.com
AI Summary
AI-generated1/39
minorbullishinsider transaction
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
OKYO Pharma Chief Scientific Officer Raj Patil purchased 3,363 ordinary shares at $1.49 per share, increasing his total holding to 20,030 shares.
The company is a clinical-stage biopharmaceutical firm focused on therapies for neuropathic corneal pain and anterior segment eye diseases.
OKYO plans to initiate a global Phase 3 pivotal clinical trial for urcosimod in the second half of 2026, targeting approximately 111 patients.